-
Mashup Score: 5BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company - 5 hour(s) ago
SAN FRANCISCO — Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical has done all that, but finds itself navigating …
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 11China's biotech boom is threatening US drugmakers' dominance - 1 day(s) ago
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers. Shortly after, they did what many researchers …
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
Very insightful piece here by @Jared_Whitlock on the growing #biotech competition in China. What Mark McKenna called an existential threat to US biotech at JPM25. They move faster, cheaper and better. https://t.co/1W4PwGdrqO
-
-
Mashup Score: 2US withdrawal from WHO could jeopardize information sharing - 2 day(s) ago
The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health information that’s vital for pharmaceutical companies, academics said Tuesday.
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet-
US withdrawal from WHO could jeopardize information sharing https://t.co/j1C3jhD2Zt
-
-
Mashup Score: 9Sionna and Odyssey end JPM week with IPO filings - 2 day(s) ago
Sionna Therapeutics and Odyssey Therapeutics join Metsera and Maze in filing for IPOs, with Sionna focused on cystic fibrosis and Odyssey on immunology treatments.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
The January testing of the #biotech IPO market is underway. Can they get out there and keep their stock price up? Or trip and fall? https://t.co/a74f0dfomU
-
-
Mashup Score: 7
Rob Califf officially ends his tenure as FDA commissioner on Monday, but in his final media event, he stressed that the US is still struggling to fight misinformation online.
Source: endpts.comCategories: General Medicine News, Expert PicksTweet-
RT @ZacharyBrennan: Departing FDA commissioner: 'We're losing the battle on misinformation' - https://t.co/qkYKxbe4Qo
-
-
Mashup Score: 8
Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the risk of further eroding faith in vaccines.
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet-
“I’ve been very clear he shouldn’t be health secretary,” https://t.co/0EKDVaXEYa
-
-
Mashup Score: 2
Pfizer and GSK’s RSV vaccines have a new warning at the request of the FDA, relaying an increased risk to Guillain-Barré syndrome within the first 42 days post-vaccination.
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet-
“The label warning follows a bleak second vaccination season for RSV makers, marked by tightened guidance, significantly less uptake and now a safety warning” https://t.co/u8BrM40yih
-
-
Mashup Score: 8
Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a neuroscience spinoff and running into a dealmaking hurdle with the FTC.
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
First biotech IPO of 2025; but we'll likely see a queue forming (already has) testing the market. I suspect solid human data will still be required for success, but let me know if you disagree. January is full of promise, December we lick wounds. https://t.co/3TyuChTUOG
-
-
Mashup Score: 0FDA offers suite of new guidance on AI, accelerated approvals, clinical trials and more - 17 day(s) ago
The FDA released dozens of new draft and final guidance documents covering everything from how to reliably use AI in drug development to how the FDA determines when a confirmatory trial is considered underway for an accelerated approval
Source: endpts.comCategories: General Medicine News, General HCPsTweet-
@US_FDA offers suite of new guidance on AI, accelerated approvals, clinical trials and more https://t.co/GZYRNeKUcQ via @ZacharyBrennan
-
-
Mashup Score: 4
BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with Pfizer to reimburse portions of both payments.
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet-
“BioNTech has entered into settlement agreements with the NIH and the University of Pennsylvania, marking a key turning point in the long-running disputes and the inking of royalty payments.” https://t.co/GfKMyKXSsj
-
One of the big themes right now in biotech: China deals. "I don’t think BioMarin’s ever done a deal with a Chinese company. We’re definitely looking.” James Sabry chats with @AndrewE_Dunn about his new work at BioMarin. https://t.co/yTyqlKS0Ym